The NCI-60 cancer cell line panel provides a premier model for data integration and systems pharmacology being the largest publicly available database of anticancer drug activity, , genomic, molecular, and phenotypic data. It comprises gene expression (25,722 transcripts), microRNAs (360 miRNAs), whole genome DNA copy number (23,413 genes), whole exome sequencing (variants for 16,568 genes), protein levels (94 genes), and cytotoxic activity input genes, microRNAs, and compounds in a single query, iii) "Pattern comparison" to identify connections among drugs, gene expression, genomic variants, microRNA and protein expressions, iv) "Genetic variation versus drug visualization" to identify potential new drug:gene DNA variant relationships, and v) "Genetic variant summation", designed to provide a synopsis of mutational burden on any pathway or gene group for up to 150 genes. Together, these tools allow users to flexibly query the NCI-60 data for potential relationships between genomic, molecular and pharmacological parameters in a manner specific to the user's area of expertise. Examples for both gain-(RAS) and loss-(PTEN) of-function alterations are provided.
Introduction
drug target CTLA4, microRNA 514, and drug hypothemycin are all novel correlations, and illustrate the potential for of Pattern Comparison as a discovery tool.
Exome Sequencing (DNA) Graphical Synopsis by Gene
To provide the user a visual summary of the genetic variants that occur within a gene as identified in our exome sequencing study, we developed "Exome sequencing (DNA) graphical synopsis by gene" (10). This tool is selected by checking its box as shown in Fig. 3A . Identifier input and data retrieval are as described for Fig (KRAS) . Note that in general, inactivating mutations tend to be more widespread for tumor suppressor genes as seen for TP53, while activating mutations tend to congregate for oncogenes, as seen for KRAS codon 12, with mutations in seven cell lines. This may be expected to be the case for the important, although uncommon, neomorphic (gain of novel gene function) mutations as well.
Genetic Variant Versus Drug Visualization
Designed to explore potential gene-drug relationships, "Genetic variant versus drug visualization" provides a visualization that compares variants for a given gene to shifts in activity for a given compound (14). This tool is selected as shown in Fig. 3C .
Using this tool, previously recognized (proof-of-principle) relationships may be observed, as for the protein kinase BRAF and the MEK (MAP2K1, 3, and 6)-ERK (MAPK1, 3, 4 and 15) inhibitor hypothemycin (10). Novel plausible relationships may also be discovered, such as between the DNA repair gene MUS81 and the DNA synthesis inhibitor clofarabine. Another example of this type is the pro-apoptotic STAT2 and the alkylating agent uracil mustard.
STAT2 has had prior reported association with DNA synthesis inhibitors (31); however genes that affect apoptosis might be expected to influence the response to multiple drug types. In addition, one can identify unstudied compounds that may target potentially pharmacologically useful genes, such as the epithelial-mesenchymal associated tight junction protein 3 (TJP3).
Introduced here, this tool also allows the user to query a single gene versus all compounds (example input, *:BRAF) or a single drug versus all genes (example input, 123127:*). These inputs will identify all correlated drugs for the *:BRAF example, or genes for the 123127:* (doxorubicin) example. Queried in this fashion, BRAF identifies 38 correlated drugs, and doxorubicin identifies four genes. The criteria for inclusion using this function include a Mathew's correlation coefficients (MCC) of ≥ 0.596 (p ≤ 0.0002 for n = 35), and are the gene-compound pairings in Table 3 and Supplementary Tables S4A and B of our prior manuscript (14). Outputs of this type with more than 150 matches will be received as a summary sheet.
Consideration of Inter-parameter Relationships: RAS Activation
In addition to the consideration of individual molecular events involved in either cancer progression or pharmacological response, CellMiner provides an opportunity to examine the contribution of multiple molecular events and forms of data simultaneously. A simple example that also illustrates the complexity of considering overlapping molecular events is provided by consideration of whether RAS is activated across these cancer cell lines. The three forms of RAS, H, K, and N, are well-studied, important oncogenes (32).
Research. Three forms of data provided by the "Cell line signature" tool ( Fig. 4A ) are informative for this purpose, DNA copy number, gene transcript levels, and activating mutations (from the "Genetic variant summation" tool). Reviewing shifts in copy number from 2N from the "Gene DNA copy number" option, in its "Graphical Output" worksheet, one finds amplifications for all three forms of RAS. Examples are given for each gene in Fig. 4B . Reviewing those data systematically, one, six, and five of the cell lines appear to have DNA amplifications for HRAS, KRAS, and NRAS, respectively (Fig. 4C) . Next, by observing the transcript levels using the "Gene transcript z scores" option, it is apparent that each of these RAS amplified cell lines also have up-regulated mRNA expression. In addition, one and four additional cell lines (without DNA amplifications) are found to have up-regulated transcript levels in HRAS and NRAS, respectively ( Fig. 4C) . Finally, by determining the presence of activating mutations (those with amino acid changes at 12, 13, and 61) using the "Genetic variant summation" option, one, ten, and two of the cell lines appear to be activated genetically in HRAS, KRAS, and NRAS, respectively ( Fig. 4C ). Viewing these data in aggregate ( Data" tool. To access this tool, click on the "Query Genomic Data" tab (with red fill). In "Step 1", the type of identifier to be used is selected. One may choose from the options shown, with the choice being dependent on the data set to be selected. In "Step 2", the identifiers are entered.
In "
Step 3", the data set of interest is selected. Currently there are 17 data sets, with only one being shown in the figure due to size constraints. In "Step 4", the user enters their e-mail address, and clicks "Get data". B. The "Query Drug Data" tool. To access this tool, click on the "Query Drug Data" tab (with red fill). In "Step 1", the type of identifier to be used is selected from the options shown. In "Step 2", the identifiers are entered. In "Step 3", the user enters their e-mail address, and clicks "Get data". Tools". To access this tool, click on the "NCI-60 Analysis Tools" tab (with red fill). In "Step 1", the type of analysis to be done is selected from the options shown. The identifiers used in these tools are available from the "Identifiers and drug mechanism of action definitions" download. In "Step 2", the user selects whether to input the identifiers as a list or as an uploaded file, and the identifiers are entered or uploaded. In "Step 3", the user enters their email address, and clicks "Get data". B. The "Cell line signature" tool. To access this tool, click on the "NCI-60 Analysis Tools" tab, followed by the "Cell line signature" check box. Select from the six forms of signatures using the radio buttons. Identifier input and data receipt is done as in Fig. 2A . C. Bar graph examples for the five forms of molecular data, plus the compound activities available currently. In all bar-plot outputs, the x-axis indicates higher levels to the right, and lower levels to the left. The y-axis is the 60 cell lines, organized by tissue of origin.
The red star next to "Protein" indicates it is a new output (introduced here).
Research. 
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